Home » Stocks » AMRX

Amneal Pharmaceuticals, Inc. (AMRX)

Stock Price: $4.41 USD -0.26 (-5.57%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $4.52 +0.11 (2.49%) Oct 28, 7:50 PM

Stock Price Chart

Key Info

Market Cap 1.32B
Revenue (ttm) 1.74B
Net Income (ttm) -194.06M
Shares Out 147.54M
EPS (ttm) -1.37
PE Ratio n/a
Forward PE 8.55
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $4.41
Previous Close $4.67
Change ($) -0.26
Change (%) -5.57%
Day's Open 4.53
Day's Range 4.40 - 4.68
Day's Volume 1,833,784
52-Week Range 2.40 - 5.79

More Stats

Market Cap 1.32B
Enterprise Value 4.02B
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 147.54M
Float 94.43M
EPS (basic) -1.51
EPS (diluted) -1.37
FCF / Share 1.93
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 21.48%
Payout Ratio n/a
Shares Short 6.26M
Short Ratio 5.75
Short % of Float 6.62%
Beta 1.49
PE Ratio n/a
Forward PE 8.55
P/FCF Ratio 4.66
PS Ratio 0.76
PB Ratio 2.51
Revenue 1.74B
Operating Income -66.87M
Net Income -194.06M
Free Cash Flow 283.82M
Net Cash -2.70B
Net Cash / Share -9.02
Gross Margin 28.58%
Operating Margin -3.85%
Profit Margin -11.20%
FCF Margin 16.32%
ROA 1.79%
ROE -58.39%
ROIC 6.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (12)

Buy 2
Overweight 0
Hold 8
Underweight 0
Sell 2

Analyst Consensus: Hold

Price Target

(4.54% upside)
Current: $4.41
Target: 4.61
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-2.2%60.88%1.52%18.33%9.53%-
Gross Profit353716526597352448
Operating Income-249-19.6724528569.57219
Net Income-362-20.92--39.00177
Shares Outstanding13212771.8671.1569.64-
Earnings Per Share-2.74-0.16-6.53-6.630.54-
Operating Cash Flow1.7125023411592.45112
Capital Expenditures-47.18-57.74-94.77-123-25.20-79.38
Free Cash Flow-45.48192139-7.7067.2532.87
Cash & Equivalents15321977.9218065.11-
Total Debt2,7662,6911,4858311,012-
Net Cash / Debt-2,613-2,473-1,407-651-947-
Book Value232505-386624-195-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Amneal Pharmaceuticals, Inc.
Country United States
Employees 5,500
CEO Chintu Patel / Chirag K. Patel

Stock Information

Ticker Symbol AMRX
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: AMRX


Amneal Pharmaceuticals, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.